A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas

Journal of Experimental and Clinical Cancer Research

Volumn 18, Issue 3, 1999, Pages 403-416

  Rieske, P ^a   Bartkowiak, J K ^a   Szadowska, A M ^a   Olborski, B ^a   Harezga Bal, B ^a   Debiec Rychter, M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

MDM2 amplification; P53 mutations; P53 MDM2 immunoreactivity; Soft tissue sarcomas

Indexed keywords

HETERODUPLEX; PROTEIN P53;

ADULT; AGED; ARTICLE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; DERMATOFIBROSARCOMA; DNA MUTATIONAL ANALYSIS; FEMALE; FIBROSARCOMA; GENE AMPLIFICATION; GENES, P53; HETERODUPLEX ANALYSIS; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RNA SPLICING; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032710251     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.M.: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992.
2. Xiao Z-X., Chen J., Levine A.J., Modjtahedl N., Xing J., Sellers W.R., Livingston D.M.: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375: 694-698, 1995.
3. Kastan M.B., Zhan Q., El-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunket B.S., Vogelstein B., Fornace A.J.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71: 587-597, 1992.
4. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parson R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B.: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
5. Zhan Q., Fan S., Bae I., Guillouf C., Liebermann D.A., O'Connor P.M., Forance A.J.: Induction of BAX by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751, 1994.
6. Barak Y., Juven T., Haffner R., Oren M.: MDM2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468, 1993.
7. Chen C.Y., Oliner J.D., Zhan Q., Fornace A.J., Vogelsttein B., Kastan M.B.: Interactions between p53 and MDM2 in mammalian cell cycle check point pathway. Proc. Natl. Acad. Sci. USA 91: 2684-2688, 1994.
8. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B.: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
9. Landers J.E., Haines D.S., Strauss J.F., George D.L.: Enhanced translation: A novel mechamism of mdm2 oncogene overexpression identified in human tumor cells. Oncogene 9: 2745-2750, 1994.
10. Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B.: Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857-860, 1993.
11. Wu X., Bayle J.H., Olson D., Levine A.J.: The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7: 1126-1129, 1993.
12. Andreassen A., Oyjord T., Howig E., Holm R., Florenes A., Nesland J.M., Myklebost O., Hoie J., Bruland A., Borresen A-L., Fodstad O.: p53 abnormalities in different sybtypes of human sarcomas. Cancer Res. 53: 468-471, 1993.
13. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M.R., Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan M.F., Levine A.J.: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54: 794-799, 1994.
14. Dei Tos A.P., Doglioni C., Piccinin S., Maestro R., Mentzel T.H., Barbareschi M., Boiocchi M., Fletcher C.D.M.: Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol. 181: 8-13, 1997.
15. Latres E., Drobnjak M., Pollack D., Oliva M.R., Ramos O., Karpeh M., Woodruff J.M., Cordon-Cardo C.: Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am. J. Pathol. 145: 345-355, 1994.
16. Reid A.H., Tsai M.M., Venzon D.J., Wright C.F., Lack E.E., O'Leary T.J.: MDM2 amplification,P53 mutation,and accumulation of the P53 gene product in malignant fibrous histiocytoma. Diag. Mol. Pathol. 5: 65-73, 1996.
17. Taubert H., Wurl P., Meyer A., Berger D., Thamm B., Neumann K., Hinze R., Schmidt H., Rath F-W.: Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma. Identification of seven new mutations for soft tissue sarcomas. Cancer 76: 1187-1196, 1995.
18. Toguchida J., Yamaguchi T., Ritchie B., Beauchamp R.L., Dayton S.H., Herrera G.E., Yamamuro T., Kotoura Y., Sasaki M.S., Little J.B., Weichselbaum R.R., Ishizaki K., Yandell D.W. : Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52: 6194-6199, 1992.
19. Florenes V.A., Maelandsmo G.M., Forus A., Andreassen A., Myklebost O., Fodstad O.: MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J. Natl. Cancer Inst. 86: 1297-1302, 1994.
20. Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B.: p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53: 2231-2234, 1993.
21. Lonardo F., Ueda T., Huvos A.G., Healey J., Ladanyi M.: P53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate. Cancer 79: 1541-1547, 1997.
22. Pilotti S., Della Tore G., Lavarino C., Di Palma S., Sozzi G., Minoletti F., Rao S., Pasquini G., Azzarelli A., Rilke F., Pierotti M.A.: Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J. Pathol. 181: 14-24, 1997.
23. Enzinger F.M., Weiss S.W.: Soft tissue tumors, 3rd edn., St. Louis, Baltimore: Mosby, 1995.
24. Bosari S., Viale G., Roncalli M., Graziani D., Borsani G., Lee A. K. C., Coggi G.: p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147: 790-798, 1995.
25. Esrig D., Spruck III C. H., Nichols P. W., Chaiwun B., Steven K., Groshen S., Chen S-C., Skinner D. G., Jones P. A., Cote R.J.: p53 nuclear protein accumulation correlates with mutation in the p53 gene, tumor grade, and stage in bladder cancer. Am. J. Pathol. 143: 1389-1397, 1993.
26. Goldman S. C., Chen C-Y., Lansing T. J., Gilmer T. M., Kastan M. B.: The p53 transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol. 148: 1381-1385, 1996.
27. Kawai M. D., Noguchi M., Beppu Y,. Yokoyama Y., Mukai K., Hirohashi S., Inoue H., Fukuma H.: Nuclear immunoreaction of p53 protein in soft tissue sarcomas. Cancer 73: 2499-2505, 1994.
28. Yoo J., Lee H.K., Kang C.H.S., Park W.S., Lee J.Y., Shim S.I.: p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch. Pathol. Lab. Med. 121: 395-399, 1997.
29. Sambrook J., Fritsch E.F., Maniatis T.: Molecular cloning. A laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989.
30. Orita M., Suzuki Y., Sekyia T., Hayashi K.: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989.
31. Soto D., Sukumar S.: Improved detection of mutation in the p53 gene in human tumors as single strand conformation polymorphism and double strand heteroduplex DNA. PCR Meth. Appl. 2: 96-98, 1992.
32. Hunter S.B., Abbott K., Varma V.A., Olson J.J., Barnett D.W., James C.D.: Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropathol .Exp. Neurol. 54: 57-64, 1995.
33. Stratton M.R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C.D.M., Ball A., Thomas M., Gusterson B. A., Cooper C.S.: Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 5: 1297-1301, 1990.
34. Hartmann A., Blaszyk H., McGovern R.M., Schroeder J.J., Cunningham J., De Vries E.M.G., Kovach J.S., Sommer S.S.: P53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10: 681-688, 1995.
35. Nakayama T, Toguchida J, Wadayama B, Kaone H, Kotoura Y, Sasaki MS. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose tissue tumors. Int J Cancer 1996; 64: 342-246
36. Miller C.W., Aslo A., Won A., Tan M., Lampkin B., Koeffler P.: Alterations of the p53, Rb, and MDM2 gene in osteosarcomas. J. Cancer Clin. Oncol. 122: 559-565, 1996.
37. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D.: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
38. Sigalas I., Calvert A.H., Anderson J.J., Neal D.E., Lunec J.: Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med. 2: 912-917, 1996.
39. Matsumoto R., Tada M., Nozaki M., Zhang C-L., Sawamura Y., Abe H.: Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res. 58: 609-613, 1998.
40. Haupt Y., Maya R., Kazaz A., Oren M.: MDM2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
41. Berberich S., Cole M.: The mdm-2 oncogene is translocated and overexpressed in a murine plasmocytoma cell line expressing wild-type p53. Oncogene 9: 1469-1472, 1994.
42. Maestro R., Gloghini A., Dogliono C.: MDM2 overexpression does not account for stabilization of wild type p53 protein. Blood 11: 3329-3334, 1995.
43. Martin K., Trouche D., Hagemeier C., Sorensen T.S., La Thangue N.B., Kouzarides T.: Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375: 691-694, 1995.
44. Dubs-Poterszman M.C., Tocque B., Wasylyk B.: MDM2 transformation in the absence of p53 and abrogation of the p107 G1cell cycle arrest. Oncogene 11: 2445-2449, 1995.
45. Kubbutat M.H., Jones S.N., Vousden K.H.: Regulation of p53 stability by mdm2. Nature 387: 296-299, 1997.
46. Prives C.: Signaling to p53: breaking the MDM2-p53 circuit. Cell 95: 5-8, 1998.